Treating Children With Radioactive Iodine Raises Secondary Primary Cancer Risk

by VR Sreeraman on  September 23, 2012 at 1:26 PM Child Health News
RSS Email Print This Page Comment
A new study has found that treating children and young adult thyroid cancer patients with radioactive iodine may raise the risk of developing a second primary malignancy.
 Treating Children With Radioactive Iodine Raises Secondary Primary Cancer Risk
Treating Children With Radioactive Iodine Raises Secondary Primary Cancer Risk

"The expected survival time for young patients with differentiated thyroid cancer is long. However, as new data elucidates, a need exists to judiciously weigh the benefits of radioactive iodine against the small, but real, increase in the risk of developing secondary primary malignancies," said Elizabeth Pearce, MD, of Boston Medical Center, and Program Co-Chair of the ATA Annual Meeting.

Though increasingly used as a treatment for differentiated thyroid cancer, long-term implication of radioactive iodine in children and young adults are not well defined. Existing data are limited to case series with limited follow-up that, in particular, may underestimate the risk of these patients developing secondary primary malignancies. To date, epidemiologic analyses of secondary primary malignancies risk have only been performed in the adult population.

A team of researchers led by Jennifer Marti, MD, of Beth Israel Medical Center in New York, thus sought to characterize of secondary primary malignancies among children. They analyzed 3,850 children and young adult patients (< 25 years old) with differentiated thyroid cancer who were followed in the NCI SEER cancer registry from 1973 to 2008. Among patients who were treated with radioactive iodine, researchers observed 26 cases of secondary primary malignancies, outnumbering the 18.3 cases researchers had expected. Researchers found that patients who were treated with radioactive iodine (40%) had a significantly elevated relative risk (SIR 1.42, p = .05) of developing a secondary primary malignancy at all sites; their risk of developing a salivary malignancy was especially elevated (SIR = 34.12, p < 0.001). Researchers also estimated that over a decade, ~1 in 227 children and young adults will develop a secondary primary malignancy attributed to radioactive iodine treatment and ~1 in 588 will develop a salivary cancer attributable to radioactive iodine treatment. Patients who were not treated with radioactive iodine did not have an elevated risk of developing a secondary primary malignancy.

Source: Newswise

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Iodine Deficiency Disorder Cancer and Homeopathy Height and Weight-Kids Cancer Facts Cancer Tattoos A Body Art Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive